ENG/中
老虎證券
市场
行情
24/7新闻
产品
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
澳股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
CLARITY PHARMACEUTICALS LTD
1.825
+0.010
0.55%
成交量:
370.71萬
成交額:
679.51萬
市值:
6.79億
市盈率:
-6.26
高:
1.910
開:
1.855
低:
1.785
收:
1.815
52周最高:
4.260
52周最低:
1.340
股本:
3.72億
流通股本:
2.74億
量比:
0.84
換手率:
1.35%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.291
每股收益(LYR):
-0.291
淨資產收益率:
-77.54%
總資產收益率:
-45.12%
市淨率:
3.65
市盈率(LYR):
-6.26
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
Cu-64 SAR-Bispsma獲FDA突破性療法認定,系PSMA PET成像領域首例,用於前列腺癌生化復發
美股速递
·
11/12
Clarity Pharmaceuticals關鍵試驗數據亮眼:8 GBq劑量下,PSA25、PSA50、PSA75及PSA90應答率分別達74%、63%、53%和26%
美股速递
·
08/05
Clarity Pharmaceuticals:8 Gbq劑量下81%疾病控制率,31%完全緩解/疾病不可檢測
美股速递
·
08/05
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www-web.itiger.com/hant/stock/CU6.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":1.825,"timestamp":1794805920000,"preClose":1.815,"halted":0,"volume":3707100,"delay":0,"changeRate":0.005509641873278242,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.291397,"marketStatus":"已收盤","change":0.01,"latestTime":"11-16 16:12:00 AEDT","open":1.855,"high":1.91,"low":1.785,"amount":6795121,"amplitude":0.068871,"askPrice":1.83,"askSize":10000,"bidPrice":1.82,"bidSize":10534,"shortable":3,"etf":0,"ttmEps":-0.291397,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1794870000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":1.815,"openAndCloseTimeList":[[1794783600000,1794805200000]],"volumeRatio":0.837357,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CU6.AU","preClose":1.815,"auctionPrice":1.825,"auctionVolume":140225,"auctionTime":1794805802430,"referencePrice":1.825,"referenceTime":1794825003103,"auction":3,"marketStatus":"盘后竞价","timestamp":1794805802430}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-45.12%","roe":"-77.54%","lyrEps":-0.291397,"volumeRatio":0.837357,"shares":372030071,"dividePrice":0,"high":1.91,"amplitude":0.068871,"preClose":1.815,"low":1.785,"week52Low":1.34,"pbRate":"3.65","psRate":"64.50","week52High":4.26,"institutionHeld":0,"latestPrice":1.825,"committee":0.026006,"eps":-0.291397,"divideRate":0,"volume":3707100,"delay":0,"ttmEps":-0.291397,"open":1.855,"prevYearClose":3.38,"prevWeekClose":1.815,"prevMonthClose":1.57,"prevQuarterClose":2.1,"fiveDayClose":1.57,"twentyDayClose":1.79,"sixtyDayClose":2.39,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1116255474","title":"Cu-64 SAR-Bispsma獲FDA突破性療法認定,系PSMA PET成像領域首例,用於前列腺癌生化復發","url":"https://stock-news.laohu8.com/highlight/detail?id=1116255474","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116255474?lang=zh_tw&edition=fundamental","pubTime":"2026-11-12 22:02","pubTimestamp":1794492133,"startTime":"0","endTime":"0","summary":"Cu-64 SAR-Bispsma斩获FDA突破性疗法认定,成为PSMA PET成像领域首个获此资格的药物,适应症为前列腺癌生化复发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187278949","title":"Clarity Pharmaceuticals關鍵試驗數據亮眼:8 GBq劑量下,PSA25、PSA50、PSA75及PSA90應答率分別達74%、63%、53%和26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187278949","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187278949?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 21:10","pubTimestamp":1785935406,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals在SECuRE试验中取得重大进展——在8 GBq剂量方案下,患者PSA25应答率高达74%,PSA50为63%,PSA75达到53%,而PSA90应答率也录得26%的亮眼表现。这一数据展现出该药物在前列腺癌治疗领域令人瞩目的潜力,为后续临床开发与商业化铺就了坚实基石。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175170356","title":"Clarity Pharmaceuticals:8 Gbq劑量下81%疾病控制率,31%完全緩解/疾病不可檢測","url":"https://stock-news.laohu8.com/highlight/detail?id=1175170356","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175170356?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 21:06","pubTimestamp":1785935169,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals的研究数据显示,在8 Gbq剂量下,患者疾病控制率高达81%。更令人振奋的是,完全缓解或疾病达到不可检测状态的比例达到了31%。这一结果无疑为该公司在癌症治疗领域的探索注入了强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CU6.AU\",params:#limit:6,delay:true,,,undefined,":[]}}